Q1 EPS Estimates for Haemonetics Cut by Barrington Research

Haemonetics Corporation (NYSE:HAE - Free Report) - Barrington Research dropped their Q1 2026 earnings per share (EPS) estimates for Haemonetics in a research report issued to clients and investors on Friday, July 11th. Barrington Research analyst M. Petusky now expects that the medical instruments supplier will post earnings per share of $1.02 for the quarter, down from their previous forecast of $1.05. Barrington Research has a "Outperform" rating and a $95.00 price target on the stock. The consensus estimate for Haemonetics' current full-year earnings is $4.55 per share. Barrington Research also issued estimates for Haemonetics' Q1 2027 earnings at $1.13 EPS, Q2 2027 earnings at $1.33 EPS, Q3 2027 earnings at $1.49 EPS and Q4 2027 earnings at $1.45 EPS.

HAE has been the topic of several other reports. Wall Street Zen lowered Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. Robert W. Baird started coverage on Haemonetics in a research report on Thursday, June 26th. They issued an "outperform" rating and a $87.00 target price on the stock. Citigroup upgraded Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 target price on the stock in a research report on Wednesday, July 9th. Baird R W upgraded Haemonetics to a "strong-buy" rating in a research report on Wednesday, June 25th. Finally, Needham & Company LLC decreased their target price on Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $97.30.

Haemonetics Price Performance

HAE traded down $0.13 during trading on Monday, hitting $74.50. The company's stock had a trading volume of 260,261 shares, compared to its average volume of 674,142. The company has a current ratio of 1.62, a quick ratio of 0.99 and a debt-to-equity ratio of 1.12. Haemonetics has a twelve month low of $55.30 and a twelve month high of $94.99. The business's fifty day simple moving average is $71.23 and its 200 day simple moving average is $67.94. The firm has a market capitalization of $3.58 billion, a price-to-earnings ratio of 22.50, a P/E/G ratio of 1.24 and a beta of 0.39.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, beating the consensus estimate of $1.22 by $0.02. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The company had revenue of $330.60 million for the quarter, compared to analyst estimates of $329.38 million. During the same period last year, the company earned $0.90 earnings per share. Haemonetics's quarterly revenue was down 3.5% compared to the same quarter last year.

Hedge Funds Weigh In On Haemonetics

A number of institutional investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. acquired a new stake in Haemonetics during the fourth quarter worth $19,002,000. AlphaQuest LLC increased its stake in Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after acquiring an additional 1,826 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Haemonetics by 10.7% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,460 shares of the medical instruments supplier's stock worth $973,000 after acquiring an additional 1,202 shares during the last quarter. HighTower Advisors LLC increased its stake in Haemonetics by 7.8% during the fourth quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock worth $262,000 after acquiring an additional 244 shares during the last quarter. Finally, Swiss National Bank increased its stake in Haemonetics by 1.2% during the fourth quarter. Swiss National Bank now owns 100,700 shares of the medical instruments supplier's stock worth $7,863,000 after acquiring an additional 1,200 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.